South Dakota Investment Council Sells 3,695 Shares of Lantheus Holdings, Inc. $LNTH

South Dakota Investment Council reduced its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 14.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 22,459 shares of the medical equipment provider’s stock after selling 3,695 shares during the quarter. South Dakota Investment Council’s holdings in Lantheus were worth $1,838,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of LNTH. TD Asset Management Inc boosted its stake in shares of Lantheus by 1,028.0% in the 1st quarter. TD Asset Management Inc now owns 682,614 shares of the medical equipment provider’s stock valued at $66,623,000 after purchasing an additional 622,100 shares during the last quarter. Nuveen LLC bought a new stake in shares of Lantheus in the 1st quarter valued at $55,941,000. Epoch Investment Partners Inc. bought a new stake in shares of Lantheus in the 1st quarter valued at $35,548,000. Mackenzie Financial Corp boosted its stake in shares of Lantheus by 129.2% in the 1st quarter. Mackenzie Financial Corp now owns 497,437 shares of the medical equipment provider’s stock valued at $48,550,000 after purchasing an additional 280,381 shares during the last quarter. Finally, Nitorum Capital L.P. bought a new stake in shares of Lantheus in the 1st quarter valued at $23,261,000. 99.06% of the stock is owned by institutional investors.

Lantheus Stock Performance

Shares of LNTH stock opened at $56.82 on Tuesday. The firm has a 50-day moving average of $54.15 and a 200-day moving average of $69.56. The company has a market cap of $3.86 billion, a P/E ratio of 15.11 and a beta of 0.09. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.29 and a quick ratio of 4.07. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $118.21.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 EPS for the quarter. The company had revenue of $92.51 million during the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. Equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. William Blair reissued a “market perform” rating on shares of Lantheus in a research note on Wednesday, July 16th. B. Riley dropped their price objective on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a research note on Tuesday, September 16th. The Goldman Sachs Group set a $77.00 price objective on shares of Lantheus and gave the company a “neutral” rating in a research note on Wednesday, October 8th. Truist Financial set a $63.00 price objective on shares of Lantheus and gave the company a “hold” rating in a research note on Monday, August 11th. Finally, TD Cowen dropped their price objective on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, September 15th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $74.50.

Insider Activity

In other news, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares in the company, valued at $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Rajiv A. Patel sold 3,365,000 shares of the stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the transaction, the insider owned 3,477,227 shares of the company’s stock, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 6,812,000 shares of company stock valued at $382,427,380. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.